These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1280 related articles for article (PubMed ID: 8873049)

  • 1. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine.
    Knight BC; Souberbielle BE; Rizzardi GP; Ball SE; Dalgleish AG
    Melanoma Res; 1996 Aug; 6(4):299-306. PubMed ID: 8873049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.
    Labarthe MC; Halanek N; Birchall L; Russell N; Desel C; Todryk S; Peters MJ; Lucas A; Falkenberg FW; Dalgleish AG; Whelan M; Ward SJ
    Cancer Immunol Immunother; 2006 Mar; 55(3):277-88. PubMed ID: 16158275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
    Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.
    Todryk SM; Birchall LJ; Erlich R; Halanek N; Orleans-Lindsay JK; Dalgleish AG
    Immunology; 2001 Feb; 102(2):190-8. PubMed ID: 11260324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice.
    Kircheis R; Küpcü Z; Wallner G; Rössler V; Schweighoffer T; Wagner E
    Cancer Gene Ther; 2000 Jun; 7(6):870-8. PubMed ID: 10880017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.
    Mac Keon S; Bentivegna S; Levy EM; Marks MS; Mantegazza AR; Wainstok R; Mordoh J
    Vaccine; 2019 Aug; 37(35):4947-4955. PubMed ID: 31307876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of intracerebral tumour protection by active-specific immunization against murine melanoma B16/G3.12.
    Staib L; Harel W; Mitchell MS
    Melanoma Res; 2001 Aug; 11(4):325-35. PubMed ID: 11479420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model.
    Souberbielle BE; Westby M; Ganz S; Kayaga J; Mendes R; Morrow WJ; Dalgleish AG
    Gene Ther; 1998 Nov; 5(11):1447-54. PubMed ID: 9930297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
    Kim TS; Russell SJ; Collins MK; Cohen EP
    Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma.
    Kim TS; Russell SJ; Collins MK; Cohen EP
    Int J Cancer; 1993 Nov; 55(5):865-72. PubMed ID: 8244584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An autologous oral DNA vaccine protects against murine melanoma.
    Xiang R; Lode HN; Chao TH; Ruehlmann JM; Dolman CS; Rodriguez F; Whitton JL; Overwijk WW; Restifo NP; Reisfeld RA
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5492-7. PubMed ID: 10779556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity.
    Todryk SM; Eaton J; Birchall L; Greenhalgh R; Soars D; Dalgleish AG; Melcher AA; Pandha HS
    Cancer Immunol Immunother; 2004 Apr; 53(4):323-30. PubMed ID: 14648067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
    Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
    J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
    Kim TS; Xu WS; Sun T; Cohen EP
    Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel murine model of allogeneic vaccination against prostate cancer.
    Labarthe MC; Theocharous P; Russell N; Todryk S; Bangma C; Thraves P; Dalgleish AG; Whelan MA
    Cancer Immunol Immunother; 2008 Apr; 57(4):453-65. PubMed ID: 17805533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.
    Kurzawa H; Wysocka M; Aruga E; Chang AE; Trinchieri G; Lee WM
    Cancer Res; 1998 Feb; 58(3):491-9. PubMed ID: 9458095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine.
    Souberbielle BE; Knight BC; Morrow WJ; Darling D; Fraziano M; Marriott JB; Cookson S; Farzaneh F; Dalgleish AG
    Gene Ther; 1996 Oct; 3(10):853-8. PubMed ID: 8908498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
    Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.